Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Bone mineral density in children and adolescents with perinatal HIV infection.

DiMeglio LA, Wang J, Siberry GK, Miller TL, Geffner ME, Hazra R, Borkowsky W, Chen JS, Dooley L, Patel K, van Dyke RB, Fielding RA, Gurmu Y, Jacobson DL; Pediatric HIVAIDS Cohort Study (PHACS).

AIDS. 2013 Jan 14;27(2):211-20. doi: 10.1097/QAD.0b013e32835a9b80.

2.

Predictors of bone mineral density in human immunodeficiency virus-1 infected children.

Jacobson DL, Spiegelman D, Duggan C, Weinberg GA, Bechard L, Furuta L, Nicchitta J, Gorbach SL, Miller TL.

J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):339-46.

PMID:
16131991
3.

Adverse bone health and abnormal bone turnover among perinatally HIV-infected Asian adolescents with virological suppression.

Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai W, Sophonphan J, Sohn AH, Ananworanich J, Puthanakit T; Bone-D Study Group.

HIV Med. 2017 Apr;18(4):235-244. doi: 10.1111/hiv.12418. Epub 2016 Aug 1.

PMID:
27477214
4.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
5.

Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.

Jacobson DL, Lindsey JC, Gordon CM, Moye J, Hardin DS, Mulligan K, Aldrovandi GM; Pediatric AIDS Clinical Trials Group P1045 team.

AIDS. 2010 Mar 13;24(5):687-96. doi: 10.1097/QAD.0b013e328336095d.

6.

Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements.

Pitukcheewanont P, Safani D, Church J, Gilsanz V.

Osteoporos Int. 2005 Nov;16(11):1393-6. Epub 2005 Feb 9.

PMID:
15702261
7.

Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir.

Nolan D, Upton R, McKinnon E, John M, James I, Adler B, Roff G, Vasikaran S, Mallal S.

AIDS. 2001 Jul 6;15(10):1275-80.

PMID:
11426072
8.

Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy.

Puthanakit T, Saksawad R, Bunupuradah T, Wittawatmongkol O, Chuanjaroen T, Ubolyam S, Chaiwatanarat T, Nakavachara P, Maleesatharn A, Chokephaibulkit K.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):477-83. doi: 10.1097/QAI.0b013e31826ea89b.

9.

Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.

Lo Re V 3rd, Guaraldi G, Leonard MB, Localio AR, Lin J, Orlando G, Zirilli L, Rochira V, Kostman JR, Tebas P.

AIDS. 2009 Oct 23;23(16):2191-8. doi: 10.1097/QAD.0b013e32832ec258.

10.

Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents.

Schtscherbyna A, Pinheiro MF, Mendonça LM, Gouveia C, Luiz RR, Machado ES, Farias ML.

Int J Infect Dis. 2012 Dec;16(12):e872-8. doi: 10.1016/j.ijid.2012.07.019. Epub 2012 Sep 30.

11.

Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Carr A, Grund B, Neuhaus J, Schwartz A, Bernardino JI, White D, Badel-Faesen S, Avihingsanon A, Ensrud K, Hoy J; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:137-46. doi: 10.1111/hiv.12242.

12.

Low Bone Mineral Density in Vertically HIV-infected Children and Adolescents: Risk Factors and the Role of T-cell Activation and Senescence.

Jiménez B, Sainz T, Díaz L, Mellado MJ, Navarro ML, Rojo P, González-Tomé MI, Prieto L, Martínez J, de José MI, Ramos JT, Muñoz-Fernandez MÁ; Madrid Cohort of HIV-Infected Children and Adolescents Integrated in the Pediatric Branch of the Spanish National AIDS Research Network (CoRISpe).

Pediatr Infect Dis J. 2017 Jun;36(6):578-583. doi: 10.1097/INF.0000000000001506.

PMID:
28005690
13.

Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.

Jacobson DL, Patel K, Siberry GK, Van Dyke RB, DiMeglio LA, Geffner ME, Chen JS, McFarland EJ, Borkowsky W, Silio M, Fielding RA, Siminski S, Miller TL; Pediatric HIV/AIDS Cohort Study.

Am J Clin Nutr. 2011 Dec;94(6):1485-95. doi: 10.3945/ajcn.111.020271. Epub 2011 Nov 2.

14.

Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.

Mulligan K, Harris DR, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, Monte D, Sleasman J, Wilson CM, Aldrovandi GM; ATN 021 Protocol team.

Clin Infect Dis. 2012 Aug;55(3):461-8. doi: 10.1093/cid/cis455. Epub 2012 May 9.

15.

Relative contribution of HIV infection, demographics and body mass index to bone mineral density.

Cotter AG, Sabin CA, Simelane S, Macken A, Kavanagh E, Brady JJ, McCarthy G, Compston J, Mallon PW; HIV UPBEAT Study Group.

AIDS. 2014 Sep 10;28(14):2051-60. doi: 10.1097/QAD.0000000000000353.

PMID:
25265073
16.

Longitudinal analysis of bone density in human immunodeficiency virus-infected women.

Dolan SE, Kanter JR, Grinspoon S.

J Clin Endocrinol Metab. 2006 Aug;91(8):2938-45. Epub 2006 May 30.

17.

Continuous antiretroviral therapy decreases bone mineral density.

Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, Martinez E, Reiss P, Visnegarwala F, Carr AD; INSIGHT SMART Body Composition Substudy Group.

AIDS. 2009 Jul 31;23(12):1519-29. doi: 10.1097/QAD.0b013e32832c1792.

18.

Impaired bone mineral accrual in prepubertal HIV-infected children: a cohort study.

Palchetti CZ, Szejnfeld VL, de Menezes Succi RC, Patin RV, Teixeira PF, Machado DM, Oliveira FL.

Braz J Infect Dis. 2015 Nov-Dec;19(6):623-30. doi: 10.1016/j.bjid.2015.08.010. Epub 2015 Oct 23.

19.

Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.

Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A.

AIDS. 2001 Sep 28;15(14):1823-9.

PMID:
11579244
20.

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.

Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL.

Pediatrics. 2006 Sep;118(3):e711-8. Epub 2006 Aug 21.

PMID:
16923923

Supplemental Content

Support Center